Andere talen Rocket Pharmaceuticals, Inc.

Aandelen

RCKT

US77313F1066

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21,52 ^USD	-1,51%		-9,08%	-28,19%

16/04	Rocket Pharmaceuticals Insider verkocht aandelen ter waarde van $1.945.785, volgens een recente SEC filing	MT
11/04	Rocket Pharmaceuticals Insider verkocht aandelen ter waarde van $308.763, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	16/04
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	11/04
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	02/04
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	26/03
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	26/03
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	26/03
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	26/03
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05/03
Rocket Pharmaceuticals Q4 Loss Narrows	26/02
Rocket Pharmaceuticals: Q4 Earnings Snapshot	26/02
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/02
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	14/02
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	13/02
FDA Extends Review of Rocket Pharma's Proposed Kresladi	13/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	13/02
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Rocket Pharmaceuticals, Inc.

Aandelen

RCKT

US77313F1066

Andere talen

Filters